Bigner S H, Humphrey P A, Wong A J, Vogelstein B, Mark J, Friedman H S, Bigner D D
Department of Pathology, Duke University Medical Center, Durham, North Carolina 27710.
Cancer Res. 1990 Dec 15;50(24):8017-22.
Both permanent cultured cell lines and athymic mouse xenografts were established from two human glioblastomas. Biopsies from D-245 MG and D-270 MG contained amplified and rearranged epidermal growth factor receptor (EGFR) genes. Although the gene amplification and rearrangement seen originally was maintained in the xenografts, cultured cell lines established from these biopsies lost the amplified rearranged genes in vitro. Analysis of these cell lines and 11 additional permanent human glioma cell lines with normal EGFR gene copy number showed from 2.7 x 10(3) to 4.1 x 10(5) high affinity EGFRs/cell by radioreceptor assay. The RNase A protection assay showed minimal differences in the quantity of EGFR mRNA among the 13 glioma lines, while the D-245 MG and D-270 MG xenografts expressed approximately 10-20 times as much EGFR mRNA as the corresponding cell lines. Immunoprecipitation of EGFR from these lines, including D-245 MG and D-270 MG, demonstrated only the intact Mr 170,000 Da form, while truncated Mr 145,000 Da and 100,000 Da EGFR proteins were immunoprecipitated from the D-270 MG and D-245 MG xenografts, respectively. These studies demonstrate that gliomas with amplification of the EGFR gene are capable of establishing in culture but that the amplified rearranged genes are not maintained. Possible explanations are that the abnormal genes are lost during serial passage or that the cells with amplified rearranged genes only represent a minor subpopulation of cells, which are unable to grow in culture. In either case, these observations suggest that high expression and structural abnormalities of EGFR proteins generated by amplification and rearrangement of the EGFR gene provide a growth advantage for gliomas in vivo but not in vitro.
从两个人类胶质母细胞瘤中建立了永久性培养细胞系和无胸腺小鼠异种移植瘤。D - 245 MG和D - 270 MG的活检样本含有扩增和重排的表皮生长因子受体(EGFR)基因。虽然最初观察到的基因扩增和重排在异种移植瘤中得以维持,但从这些活检样本建立的培养细胞系在体外失去了扩增重排的基因。对这些细胞系以及另外11个具有正常EGFR基因拷贝数的永久性人类胶质瘤细胞系进行分析,通过放射受体测定法显示每个细胞有2.7×10³至4.1×10⁵个高亲和力EGFR。核糖核酸酶A保护试验显示,在这13个胶质瘤细胞系中,EGFR mRNA的量差异极小,而D - 245 MG和D - 270 MG异种移植瘤表达的EGFR mRNA量约为相应细胞系的10 - 20倍。从这些细胞系(包括D - 245 MG和D - 270 MG)中免疫沉淀EGFR,仅显示完整的170,000 Da形式,而从D - 270 MG和D - 245 MG异种移植瘤中分别免疫沉淀出截短的145,000 Da和100,000 Da的EGFR蛋白。这些研究表明,具有EGFR基因扩增的胶质瘤能够在培养中建立,但扩增重排的基因无法维持。可能的解释是,异常基因在传代过程中丢失,或者具有扩增重排基因的细胞仅代表一小部分细胞亚群,它们无法在培养中生长。无论哪种情况,这些观察结果表明,由EGFR基因扩增和重排产生的EGFR蛋白的高表达和结构异常为胶质瘤在体内而非体外提供了生长优势。